All News
Proposed Cancer Screening for Inflammatory Myositis Patients
Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue.
Read Article
Prieto-Pena et al. Tocilizumab in GCA and TAK. Observational study of 70 GCA, 57 TAK in Spain. Similar efficacy in both diseases. @rheumnow #ACR22 Abstr#0465 https://t.co/pyKAILryhH https://t.co/Csp7FIgnzD
Richard Conway RichardPAConway ( View Tweet)
After bDMARD treatment for 1 year in AxSpA, the gut microbiota composition:
◦ more resembled controls
◦ Enrichment of Collinsella remained stable
◦ Depletion of some species in HLA-B27+ patients from baseline
https://t.co/Mw4MToqFcQ
Poddubnyy et al @ProftDr #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR22 Abs 0256 identified different autoantibodies in ACPA+ and ACPA– RA. Study shows potential utility of serum autoantibodies as diagnostic targets for RA subgroups & treatments. This study reminds me of @RheumNow teaching that not all RA created equal. https://t.co/Fjjk6uC0pB https://t.co/Ozr32cJojr
Dr. Rachel Tate uptoTate ( View Tweet)
“It's not that I'm so smart, it's just that I stay with problems longer.” Einstein
Love the quote in the community hub for early career @NIAMSFunding - Perseverance is the KEY in this funding world #ACR22 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Figueroa-Parra et al @AliDuarteMD Preventative services in SLE better in some areas and worse in some than comparators. Overall cervical screening, osteoporosis, dyslipidaemia low in this high risk group @rheumnow #ACR22 Abstr#0064 https://t.co/fHQ7ct6yt5 https://t.co/x7gHUDA8zo
Richard Conway RichardPAConway ( View Tweet)
Wilding et al. Mortality in AAV 1/5/10-year survival 90%/73%/57% in AAV, 97%/86%/73% controls (p <0.0001). Highest 1st year - often vasculitis related (35%). After this - infection (28% vs 19%) @rheumnow #ACR22 Abstr#0448 https://t.co/YwwaaB6jDS https://t.co/ogrJkLAd1v
Richard Conway RichardPAConway ( View Tweet)
Good news for patients who require short interruptions in biologic therapy!
Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease.
#Abs0427 @RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
Hajj-Ali @RulaHajjAliMD et al. Worse PROs neuro AAV. Lower SF-36 Physical Functioning, Limitations in Physical role, Bodily Pain, and PCS. Higher PROMIS pain, lower PROMIS function @rheumnow #ACR22 Abstr#0437 https://t.co/ldC2VEZ0FV https://t.co/0pdjdSZQSS
Richard Conway RichardPAConway ( View Tweet)
Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22
UPA>ADA from wk 16-56. UPA and ADA>>PBO
Strongly associates with DAPSA or MDA/VLDA composite scores
@RheumNow https://t.co/ABY12ar7RS
Eric Dein ericdeinmd ( View Tweet)
Kakoullis et al. Steroid initiation within 1 week onset of GCA symptoms associated decreased relapse OR=0.216. @rheumnow #ACR22 Abstr#0469 https://t.co/sEW1V6NRpb https://t.co/4sAYZbmHX3
Richard Conway RichardPAConway ( View Tweet)
Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI > zoster most common) Risks: ischemic heart disease, ASDAS-ESR >3.5, complicated DM, abnormal chest x-ray, current bDMARDs. Male gender was protective. Abs 0372 #ACR22 @RheumNow https://t.co/i1JyFuriFz
Dr. Rachel Tate uptoTate ( View Tweet)
Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg
Richard Conway RichardPAConway ( View Tweet)
Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthritis when given at early but not late stage in an animal model. Appears to be mediated through NETs @rheumnow #ACR22 Abstr#0045 https://t.co/HSD0oZBaha https://t.co/OqTv4XLXws
Richard Conway RichardPAConway ( View Tweet)
Bui et al. Screening for ANCA in ILD. Present in 9.8% . 65.4% of these had AAV. No difference in pulmonary outcomes. More steroids, immunosuppressives, hospitalisations. @rheumnow #ACR22 Abstr#0438 https://t.co/RGdnDWSpNF https://t.co/xYeCUoTqqy
Richard Conway RichardPAConway ( View Tweet)
Endothelin-1, pro-inflammatory protein involved in multiple vascular and fibrosing abnormalities, may be a biomarker for differentiating between IPF and IIM-ILD or SSc-ILD. I'm always interested in potential biomarkers for clinic! Abs 0123 #ACR22 @RheumNow https://t.co/I69X4V0Zoa
Dr. Rachel Tate uptoTate ( View Tweet)
BIOBADASER cohort showing risk of incident cancer in rheumatic disease and previous malignancy was not difference between TNFi and other biologics/tsDMARDs. Need bigger numbers (esp with JAKi) to really reassure.
@RheumNow ABST0267 #ACR22 #ACRBest
https://t.co/0YutuCBOb8 https://t.co/btYrCA6UDh
Julian Segan JulianSegan ( View Tweet)
#abst037 #acr22 @rheumnow REGISPONSER & RESPONDIA study of 231 pts w/late- vs early-onset PsA: late-onset> often male , ⬆️structural damage, ⬆️ FASFI, ⬆️ UE arthritis. Sacroiliitis& enthesitis ⬇️ frequent in late-onset. No effect on quality of life, dis activity & Rx choice https://t.co/IPRc1r2sxZ
Olga Petryna DrPetryna ( View Tweet)
How do we decide which RA patients are best for #telehealth?
Abstract #1291, Ignite session
🖥@DavidLeverenz et. al created a predictive model to answer this question
🖥Patient age, diagnosis, medications, and RAPID3 score impacted the model
@RheumNow #ACR22 https://t.co/JztTbQ4zfZ
Catherine Sims, MD DrCassySims ( View Tweet)
Leung et al @drceowen @drdavidliew persistence of fatigue, sleep and mood disorders in treated PMR patients in clinical remission. higher PSQI (lower quality sleep), higher BRAF (fatigue), higher HAD (depression, anxiety) @rheumnow #ACR22 Abstr#0204 https://t.co/zoeBNO6vVD https://t.co/TGC57kj6of
Richard Conway RichardPAConway ( View Tweet)